Complete resolution of severe chronic active Epstein-Barr virus infection by cultured, activated donor T lymphocyte infusion after nonmyeloablative stem cells allografting

Bone Marrow Transplantation

Volumn 32, Issue 1, 2003, Pages 107-110

  Yoshiba, F ^a   Hagihara, M ^a   Tazume, K ^a   Ogawa, Y ^a   Kishi, K ^a   Higuchi, A ^a   Kato, S ^a   Hotta, T ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CTL; Cultured T cells; GVHD; Mini transplantation; SCAEBV

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; OKT 3; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; CHIMERA; CHRONIC DISEASE; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; EPSTEIN BARR VIRUS; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL; HLA MATCHING; HUMAN; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RECIPIENT; SIBLING; STEM CELL TRANSPLANTATION; VIRUS INFECTION; VIRUS LOAD;

ADULT; CELLS, CULTURED; CHRONIC DISEASE; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE TRANSFUSION; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0038493772     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704074     Document Type: Article

References (13)

1. Okamura T, Hatsukawa Y, Arai H et al. Blood stem-cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation. Lancet 2000; 356: 223-224.
2. Fujii N, Takenaka K, Hiraki A et al. Allogeneic peripheral blood stem cell transplantation for the treatment of chronic active Epstein-Barr virus infection. Bone Marrow Transplant 2000; 26: 805-808.
3. Kimura H, Hoshino Y, Kanegane H et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 2001; 98: 280-286.
4. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
5. Straus SE. The chronic mononucleosis syndrome. J Infect Dis 1988; 157: 405-412.
6. Okano M, Matsumoto S, Osato T et al. Severe chronic active Epstein-Barr virus infection syndrome. Clin Microbiol Rev 1991; 4: 129-135.
7. Ohga S, Nomura A, Takada H et al. Epstein-Barr virus (EBV) load and cytokine gene expression in activated T cells of chronic active EBV infection. J Infect Dis 2001; 183: 1-7.
8. Falkenburg JH, Goselink HM, van der Harst D et al. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Exp Med 1991; 174: 27-33.
9. Quintanilla-Martinez L, Kumar S, Fend F et al. Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome. Blood 2000; 96: 443-451.
10. Rodriguez J, Romaguera JE, Manning J et al. Nasal-type T/NK lymphomas: a clinicopathologic study of 13 cases. Leuk Lymphoma 2000; 39: 139-144.
11. Ballen KK, Becker PS, Emmons RV et al. Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy. Blood 2002; 100: 442-450.
12. Takayama T, Sekine T, Makuuchi M et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356: 802-807.
13. Azuma H, Yamada Y, Shibuya-Fujiwara N et al. Functional evaluation of ex vivo expanded cord blood lymphocytes. Possible use for adoptive cellular immunotherapy. Exp Hematol 2002; 30: 346-351.